The safety and efficacy of DATSCAN were evaluated in two multicenter, single-arm, open-label studies (Study 1 and Study 2) that enrolled 284 adult patients with suspected PS.
In these studies, DATSCAN image interpretation was compared to a reference clinical diagnostic standard of "PS" or "non-PS". PS consisted of Parkinson's disease (PD), multiple system atrophy (MSA), and progressive supranuclear palsy (PSP). These conditions have been associated with dopaminergic neurodegeneration and DATSCAN imaging was not designed to distinguish among the conditions. Among the non-PS population, subjects with a history of the following conditions were included: vascular parkinsonism, psychogenic parkinsonism, essential tremor (ET), various forms of tremor, and other non-PS diagnoses; DATSCAN imaging was not designed to distinguish among these conditions.
Patients underwent SPECT imaging with a variety of multi-headed cameras or multi-detector single-slice systems 3 to 6 hours after DATSCAN administration. The DATSCAN activity in these two clinical studies ranged from 111 MBq to 201 MBq (3 mCi to 5.4 mCi) [median 167.8 MBq (4.5 mCi)]. Readers blinded to clinical information interpreted DATSCAN imaging as normal or abnormal [see Dosage and Administration (2.5)]. A normal image is inconsistent with clinical conditions associated with PS and an abnormal image is consistent with clinical conditions associated with PS.
Study 1 consisted of 99 patients with early features of Parkinsonism; patients with features suggestive of MSA or PSP were excluded. The baseline clinical diagnoses consisted of: probable PD (44%), possible PD (31%), "benign" PD (6%), possible ET (11%), and other diagnoses (7%). The patients were 44% female, 42% of age 65 years or over, and all were White. Study 1 readers had no other role in patient assessment. The reference clinical diagnostic standard consisted of the clinical diagnoses established by a consensus panel of movement disorder specialists that evaluated data inclusive through 36 months of follow-up.
Study 2 consisted of 185 patients with clinically established diagnosis of PS (PD, MSA, PSP) or ET. The baseline clinical diagnoses consisted of: PD (70%), MSA (10%), PSP (5%), and ET (15%). The patients were 35% female, 48% of age 65 years or over, and 99% were White. Study 2 readers included site investigators. The reference clinical diagnostic standard consisted of the investigator-determined baseline clinical diagnosis.
Table 4 shows the positive percent agreement and negative percent agreement of the DATSCAN image results with the reference clinical diagnostic standard. Positive percent agreement represents the percent of patients with abnormal DATSCAN images among all the patients with a clinical diagnostic reference standard of PS. Negative percent agreement represents the percent of patients with normal DATSCAN images among the patients with a non-PS clinical diagnostic reference standard.
Table 4: Positive and Negative Percent Agreements for Studies 1 and 2 | Positive percent agreement (95 % CI) | Negative percent agreement (95 % CI) |
|---|
| Study 1 (patients with early signs and/or symptoms of PS) |
| Reader A, n = 99 | 77 (66, 87) | 96 (82, 100) |
| Reader B, n = 96 | 78 (66, 87) | 96 (82, 100) |
| Reader C, n = 98 | 79 (67, 87) | 96 (82, 100) |
| Study 2 (patients with established diagnoses of PS or ET) |
| Reader A, n = 185 | 93 (88, 97) | 96 (81, 100) |
| Reader B, n = 185 | 97 (93, 99) | 74 (54, 89) |
| Reader C, n = 185 | 96 (92, 99) | 85 (66, 96) |
| Reader D, n = 185 | 92 (87, 96) | 93 (76, 99) |
| Reader E, n = 185 | 94 (90, 97) | 93 (76, 99) |